A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event

Investigational New Drugs

Volumn 36, Issue 1, 2018, Pages 144-146

  Gelsomino, Francesco ^a   Vitale, Giovanni ^b   Ardizzoni, Andrea ^b  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Cholangitis; Immunotherapy; Nivolumab; Non small cell lung cancer

Indexed keywords

ALKALINE PHOSPHATASE; AMINOTRANSFERASE; BILIRUBIN; CYTOKERATIN 19; CYTOKERATIN 7; GAMMA GLUTAMYLTRANSFERASE; IMMUNOGLOBULIN G4; NIVOLUMAB; PROGRAMMED DEATH 1 LIGAND 1; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BILIRUBIN BLOOD LEVEL; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHOLANGITIS; COMPUTER ASSISTED TOMOGRAPHY; DRUG SAFETY; ENZYME BLOOD LEVEL; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LABORATORY TEST; LIVER BIOPSY; LIVER FUNCTION TEST; LYMPHOCYTIC INFILTRATION; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; CASE REPORT; CHEMICALLY INDUCED; IMMUNOLOGY;

ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; CHOLANGITIS; HUMANS; NIVOLUMAB;

EID: 85021149483     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-017-0484-6     Document Type: Article

References (11)

1. Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252–264
2. Francisco LM, Sage PT, Sharpe AH (2010) The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 236:219–242
3. Brahmer JR, Tykodi SS, Chow LQ et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455–2465
4. Gettinger SN, Horn L, Gandhi L et al (2015) Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 33:2004–2012
5. Rizvi NA, Mazieres J, Planchard D et al (2015) Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 16:257–265
6. Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:123–135
7. Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627–1639
8. Spain L, Diem S, Larkin J (2016) Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 44:51–60
9. Gelsomino F, Vitale G, D’Errico A, Bertuzzi C, Andreone P, Ardizzoni A (2017) Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury. Ann Oncol 28:671–672. doi:10.1093/annonc/mdw649
10. Kawakami H, Tanizaki J, Tanaka K et al (2017) Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Investig New Drugs. doi:10.1007/s10637-017-0453-0
11. EASL Clinical Practice Guidelines: Management of cholestatic liver diseases. European Association for the Study of the Liver (2009) J Hepatol 51:237–267